The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hagan Joseph P since 2012.
This trader's CIK number is 1465278.
At the time of last reporting, Hagan Joseph P was the Chief Executive Officer of Regulus Therapeutics Inc.. (stock ticker symbol RGLS).
Also see all insider trading activities at Regulus Therapeutics Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2014 | OREX | 5,000 | $23,450 | 0 | $0 | 0 | $0 |
| 2013 | OREX | 0 | $0 | 50,000 | $363,600 | 50,000 | $83,000 |
| 2012 | OREX | 0 | $0 | 138,000 | $798,190 | 138,000 | $229,080 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | AUPH | 0 | $0 | 272 | $2,877 | 8,733 | $0 |
| 2022 | AUPH | 0 | $0 | 40,000 | $917,400 | 40,000 | $203,200 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RGLS | 50,000 | $54,250 | 0 | $0 | 0 | $0 |
| 2024 | RGLS | 0 | $0 | 14,580 | $17,364 | 0 | $0 |
| 2022 | RGLS | 100,000 | $21,500 | 0 | $0 | 0 | $0 |
| 2021 | RGLS | 0 | $0 | 8,330 | $10,852 | 0 | $0 |
| 2020 | RGLS | 0 | $0 | 27,434 | $20,174 | 0 | $0 |
| 2019 | RGLS | 33,194 | $35,849 | 69,933 | $73,405 | 0 | $0 |
| 2017 | RGLS | 219,780 | $199,999 | 0 | $0 | 0 | $0 |
| 2016 | RGLS | 10,000 | $71,900 | 0 | $0 | 0 | $0 |
1. Orexigen Therapeutics, Inc. (OREX)
2. Aurinia Pharmaceuticals Inc. (AUPH)
3. Regulus Therapeutics Inc. (RGLS)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-09-15 | OREX | Buy | 5,000 | 4.69 | 23,450 |
| 2013-07-31 | OREX | Option Ex | 12,000 | 1.66 | 19,920 |
| 2013-07-31 | OREX | Sale | 12,000 | 7.80 | 93,600 |
| 2013-07-26 | OREX | Option Ex | 10,000 | 1.66 | 16,600 |
| 2013-07-26 | OREX | Sale | 10,000 | 7.40 | 74,000 |
| 2013-05-28 | OREX | Sale | 28,000 | 7.00 | 196,000 |
| 2013-05-28 | OREX | Option Ex | 28,000 | 1.66 | 46,480 |
| 2012-07-13 | OREX | Sale | 30,000 | 6.80 | 204,000 |
| 2012-07-13 | OREX | Option Ex | 30,000 | 1.66 | 49,800 |
| 2012-06-28 | OREX | Sale | 26,000 | 5.90 | 153,400 |
| 2012-06-29 | OREX | Sale | 12,000 | 6.30 | 75,600 |
| 2012-06-27 | OREX | Option Ex | 70,000 | 1.66 | 116,200 |
| 2012-06-28 | OREX | Option Ex | 26,000 | 1.66 | 43,160 |
| 2012-06-27 | OREX | Sale | 70,000 | 5.22 | 365,190 |
| 2012-06-29 | OREX | Option Ex | 12,000 | 1.66 | 19,920 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-05-18 | AUPH | Option Ex | 8,733 | .00 | 0 |
| 2023-05-19 | AUPH | Sale | 272 | 10.58 | 2,877 |
| 2022-01-03 | AUPH | Option Ex | 40,000 | 5.08 | 203,200 |
| 2022-01-03 | AUPH | Sale | 40,000 | 22.93 | 917,400 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-30 | RGLS | Buy | 50,000 | 1.08 | 54,250 |
| 2024-01-18 | RGLS | Sale | 14,580 | 1.19 | 17,364 |
| 2022-01-26 | RGLS | Buy | 100,000 | .21 | 21,500 |
| 2021-05-17 | RGLS | Sale | 4,186 | .89 | 3,725 |
| 2021-02-16 | RGLS | Sale | 4,144 | 1.72 | 7,127 |
| 2020-11-16 | RGLS | Sale | 6,094 | .52 | 3,174 |
| 2020-08-14 | RGLS | Sale | 4,245 | .60 | 2,568 |
| 2020-05-15 | RGLS | Sale | 4,426 | .63 | 2,775 |
| 2020-02-18 | RGLS | Sale | 4,324 | .83 | 3,588 |
| 2020-01-02 | RGLS | Sale | 8,345 | .97 | 8,069 |
| 2019-11-14 | RGLS | Sale | 5,838 | .64 | 3,736 |
| 2019-10-01 | RGLS | Sale | 8,743 | .68 | 5,971 |
| 2019-08-15 | RGLS | Sale | 4,375 | .55 | 2,410 |
| 2019-07-01 | RGLS | Sale | 5,783 | 1.31 | 7,587 |
| 2019-05-16 | RGLS | Sale | 39,352 | 1.22 | 47,970 |
| 2019-05-07 | RGLS | Buy | 33,194 | 1.08 | 35,849 |
| 2019-04-01 | RGLS | Sale | 5,842 | .98 | 5,731 |
| 2017-07-25 | RGLS | Buy | 219,780 | .91 | 199,999 |
| 2016-03-03 | RGLS | Buy | 10,000 | 7.19 | 71,900 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hagan Joseph P (Chief Executive Officer of Regulus Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.